The National Institutes of Health has begun an early stage study on its experimental vaccine targeting six strains of influenza virus.

Media reports touting ketamine as a miracle drug for severe depression have contributed to confusion about the differences between ketamine and its esketamine, experts said.

'Normal' TSH and FT4 concentrations change with age, and the failure to consider those changes in assessment can lead to misdiagnosis and overtreatment.

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, independent of symptom changes, new research suggested.

An RCT suggests transcranial alternating current stimulation may be an effective treatment for major depression, but outside experts say more study is needed to confirm its benefit.

An early trial suggests a combination of psilocybin and psychotherapy may be safe and effective for treatment-resistant depression associated with bipolar II disorder and deserves further study.

The twice-yearly injectable preexposure prophylaxis demonstrated 100% efficacy at interim results. Now, specialists are sharing what they are looking forward to seeing at AIDS 2024 in Munich.

Dana-Farber Cancer Institute is investigating allegations of data manipulation in dozens of research papers, some of which were authored by high-profile investigators.

Placebo-controlled trials are insufficient for decisions that affect medication availability in EU member states.

In a proposed guidance, the FDA voiced concerns over whether cancer clinical trials largely or entirely conducted outside the United States are relevant to US patients.

0 votes and 5 comments so far on Reddit

New phase 3 results should reopen discussion about the off-label use of COMT inhibitors in early Parkinson's disease, experts said.

Studies have suggested that IL-1 beta activation leads to IL-6 production, which could provide an alternative to current therapeutic strategies.

Famed microbiome researcher Dr Martin J. Blaser shares what he sees as the most promising applications, and the rigorous clinical trials needed to realize them.

Restarting a CGRP monoclonal antibody (mAb) after a gap in treatment may lower response rate, a new study suggests. However, switching to a different mAb may counter this effect.

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped treatment stayed clear or nearly clear for 8 weeks.

Consensus was reached during an in-person meeting attended by 34 individuals with diverse backgrounds.

Also, pregnancy monitoring startup Kali Healthcare has secured pre-seed funding to enter into clinical trial phase.

Alopecia, dysesthesia, and other types of skin sensations have been reported in patients treated with semaglutide, but more research is needed to understand skin findings associated with this drug.

The medicines regulator has endorsed Merck's 21-valent pneumococcal vaccine for adults.